SCHEMBL6414420

SCHEMBL6414420

CC(=O)N1CCN(C(=O)CCN2C(=O)c3ccccc3C(C(=O)NCC3CC3)C2c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.39
FFAR1 O14842 4/20 0.39
GAA P10253 2/20 0.38
TACR1 P25103 1/20 0.37
LMNA P02545 2/20 0.37
KCNH2 Q12809 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
TP53 P04637 1/20 0.36
MDM2 Q00987 1/20 0.36
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416277 0.92 ALDH1A1 (0.42) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6419057 0.88 ALDH1A1 (0.57) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6413189 0.88 GAA (0.43) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6418311 0.86 ALDH1A1 (0.48) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6417684 0.86 TSHR (0.44) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6412345 0.83 GLA (0.47) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6411734 0.82 CCR2 (0.41) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6413158 0.81 SCN9A (0.41) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6411923 0.81 ALDH1A1 (0.58) ALDH1A1NPSR1KDM4EMAPTHTT
SCHEMBL6415209 0.81 SCN9A (0.41) ALDH1A1NPSR1KDM4EMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD ALDH1A1 1368/4885NPSR1 4805/4885KDM4E 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.